Kahn SE, et al.. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014; 383:1068–1083.

• Crossref
Kahn SE, . Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014; 383:1068–1083.10.1016/S0140-6736(13)62154-6)| false
• Search Google Scholar
• Export Citation

Andersen ES, et al.. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab 2018; 20:34–41.

• Crossref
Andersen ES, . Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab 2018; 20:34–41.10.1111/dom.13018)| false
• Search Google Scholar
• Export Citation

Davies MJ, et al.. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:2669–2701.

• Crossref
Davies MJ, . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:2669–2701.10.2337/dci18-0033)| false
• Search Google Scholar
• Export Citation

Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013; 19:1050–1061.

• Crossref
Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013; 19:1050–1061.10.4158/EP12303.RA)| false
• Search Google Scholar
• Export Citation

Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40:284–286.

• Crossref
Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40:284–286.10.2337/dc15-1707)| false
• Search Google Scholar
• Export Citation

Lee SG, et al.. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155:172–177.

• Crossref
Lee SG, . Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155:172–177.10.1001/jamadermatol.2018.4556)| false
• Search Google Scholar
• Export Citation

Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016; 18:333–347.

• Crossref
Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016; 18:333–347.10.1111/dom.12610)| false
• Search Google Scholar
• Export Citation

Rosenstock J, et al.. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38:376–383.

• Crossref
Rosenstock J, . Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38:376–383.10.2337/dc14-1142)| false
• Search Google Scholar
• Export Citation

Cooper ME, et al.. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66:441–449.

• Crossref
Cooper ME, . Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66:441–449.10.1053/j.ajkd.2015.03.024)| false
• Search Google Scholar
• Export Citation

Groop PH, et al.. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes Obes Metab 2017; 19:1610–1619.

• Crossref
Groop PH, . Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes Obes Metab 2017; 19:1610–1619.10.1111/dom.13041)| false
• Search Google Scholar
• Export Citation

Rosenstock J, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321:69–79.

• Crossref
Rosenstock J, . Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321:69–79.10.1001/jama.2018.18269)| false
• Search Google Scholar
• Export Citation

Marx N, et al.. Design and baseline characteristics of the CARdiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res 2015; 12:164–174.

• Crossref
Marx N, . Design and baseline characteristics of the CARdiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA^®). Diab Vasc Dis Res 2015; 12:164–174.10.1177/1479164115570301)| false
• Search Google Scholar
• Export Citation